Ernest J Maningding, MD
Rheumatology · Hayward
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Alameda Health System · 597 clinicians in this group
Looking this up.
Hospitals listed: Highland Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Maningding’s office at (510) 266-1700 to ask if they take your plan before you enroll.
California Medical Board record
Licence A151534 · Current
Licensed to practise in California · since 2017 · expires 2027-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Medicaid work
$168,819 in 2024
Medicaid paid $168,819 for 1,701 billed services this clinician did in 2024, up to 51 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 554 | $91,221 |
| Return visit (30+ min) | 1,147 | $77,598 |
| 2024 | 1,701 | 2 | 51 | $168,819 |
| 2023 | 1,579 | 3 | 46 | $139,264 |
| 2022 | 1,464 | 3 | 81 | $131,926 |
| 2021 | 232 | 2 | 31 | $15,274 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 598 | $99,858 |
| Return visit (30+ min) | 968 | $37,827 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 13 | $1,580 |
2022
| Clinic visit/encounter, all-inclusive | 488 | $76,276 |
| Return visit (30+ min) | 964 | $55,649 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 12 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 48 | $13,319 |
| Return visit (30+ min) | 184 | $1,955 |
Drugs they prescribed that Part D paid
$1,760,908
Pharmacies billed $1,760,908 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (12 of 879) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
589 generic and 290 brand-name prescriptions · $1,760,908 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 61 | $454,674 | $7,454 |
| Humira(Cf) | 39 | $320,235 | $8,211 |
| Humira | 30 | $217,601 | $7,253 |
| Enbrel Mini | 23 | $161,745 | $7,032 |
| Xeljanz Xr | 25 | $137,125 | $5,485 |
See all 22 drugs
| Enbrel Sureclick | 61 | $454,674 | $7,454 |
| Humira(Cf) | 39 | $320,235 | $8,211 |
| Humira | 30 | $217,601 | $7,253 |
| Enbrel Mini | 23 | $161,745 | $7,032 |
| Xeljanz Xr | 25 | $137,125 | $5,485 |
| Cosentyx Sensoready (2 Pens) | 14 | $91,844 | $6,560 |
| Taltz | 12 | $71,403 | $5,950 |
| Vemlidy | 21 | $28,046 | $1,336 |
| Rasuvo | 12 | $8,986 | $749 |
| Hydroxychloroquine Sulfate | 89 | $5,405 | $61 |
| Mycophenolate Mofetil | 22 | $4,993 | $227 |
| Leflunomide | 49 | $4,243 | $87 |
| Methotrexate | 87 | $4,029 | $46 |
| Sulfasalazine | 24 | $876 | $37 |
| Diclofenac | 38 | $587 | $15 |
| Lidocaine | 16 | $474 | $30 |
| Allopurinol | 25 | $338 | $14 |
| Gabapentin | 25 | $258 | $10 |
| Alendronate | 26 | $221 | $8 |
| Prednisone | 47 | $216 | $5 |
| Naproxen | 17 | $42 | $2 |
| Meloxicam | 19 | $33 | $2 |
Year by year
| 2024 | 879 | 113 | 1% (12) | 33% | $1,760,908 |
| 2023 | 957 | 113 | 0% (0) | 34% | $2,017,923 |
| 2022 | 939 | 109 | 0% (0) | 32% | $1,711,301 |
| 2021 | 181 | 67 | 0% (0) | None | $148,638 |
| 2020 | 35 | None | 0% (0) | 31% | $54,532 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Enbrel Sureclick | 84 | $628,741 | $7,485 |
| Humira(Cf) | 39 | $323,539 | $8,296 |
| Enbrel Mini | 25 | $192,665 | $7,707 |
| Humira | 25 | $178,677 | $7,147 |
| Cosentyx Sensoready (2 Pens) | 14 | $114,880 | $8,206 |
| Taltz | 13 | $95,812 | $7,370 |
| Xeljanz Xr | 16 | $94,089 | $5,881 |
| Vemlidy | 21 | $31,505 | $1,500 |
| Hydroxychloroquine Sulfate | 112 | $8,033 | $72 |
| Methotrexate | 91 | $7,781 | $86 |
| Rasuvo | 14 | $7,276 | $520 |
| Mycophenolate Mofetil | 13 | $3,634 | $280 |
| Leflunomide | 33 | $2,383 | $72 |
| Diclofenac | 78 | $1,883 | $24 |
| Sulfasalazine | 18 | $1,066 | $59 |
| Prednisone | 54 | $654 | $12 |
| Gabapentin | 23 | $499 | $22 |
| Alendronate | 21 | $489 | $23 |
| Lidocaine | 19 | $470 | $25 |
| Celecoxib | 11 | $384 | $35 |
| Allopurinol | 19 | $242 | $13 |
| Meloxicam | 13 | $218 | $17 |
| Hydrocortisone | 14 | $173 | $12 |
2022: 19 drugs
| Enbrel Sureclick | 76 | $520,444 | $6,848 |
| Humira(Cf) | 46 | $323,317 | $7,029 |
| Xeljanz Xr | 35 | $195,727 | $5,592 |
| Humira | 22 | $150,346 | $6,834 |
| Enbrel Mini | 17 | $119,333 | $7,020 |
| Cosentyx Pen (2 Pens) | 12 | $82,454 | $6,871 |
| Actemra Actpen | 12 | $48,577 | $4,048 |
| Hydroxychloroquine Sulfate | 105 | $9,019 | $86 |
| Methotrexate | 98 | $7,750 | $79 |
| Leflunomide | 36 | $5,088 | $141 |
| Mycophenolate Mofetil | 13 | $2,515 | $193 |
| Diclofenac | 83 | $2,450 | $30 |
| Gabapentin | 33 | $1,229 | $37 |
| Sulfasalazine | 30 | $1,065 | $36 |
| Prednisone | 74 | $860 | $12 |
| Fluocinonide | 14 | $460 | $33 |
| Alendronate | 29 | $279 | $10 |
| Hydrocortisone | 16 | $174 | $11 |
| Pantoprazole | 12 | $34 | $3 |
2021: 5 drugs
| Enbrel Sureclick | 11 | $69,694 | $6,336 |
| Methotrexate | 31 | $3,408 | $110 |
| Hydroxychloroquine Sulfate | 27 | $2,507 | $93 |
| Diclofenac | 14 | $380 | $27 |
| Prednisone | 15 | $252 | $17 |
2020: 1 drug
| Hydroxychloroquine Sulfate | 13 | $1,359 | $105 |
Money from drug and device companies
$101 in 2022
| 2022 | 1 | 1 | None | $101 |
| 2019 | 1 | 1 | None | $31 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Mavyret | $101 | 1 payment
|
See the published payment
| Abbvie | Meals · 2022-02-24 | Mavyret | $101 |
See earlier years (2019)
2019: $31
| Alexion Pharmaceuticals | Strensiq | $31 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1831551274
- Licence
- CA A151534California A151534: Current · expires 2027-09-30
- Trained
- University of California, San Francisco School of Medicine, 2015
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Student in a training program (390200000X)
- Mailing address
- 5192 Omar St, Fremont, CA, 94538
- NPI first listed
- 2016-03-24
- NPI last updated
- 2021-07-19
- NPI record certified
- 2021-07-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128